Cargando…
Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
BACKGROUND: The emergence of immune checkpoint inhibitors (ICIs) has significantly improved the clinical outcomes of patients with metastatic melanoma. However, survival benefits are only observed in a subset of patients. The fibroblast growth factor receptor (FGFR) family genes are frequently mutat...
Autores principales: | Zhang, Wengang, Xia, Handai, Yang, Rui, Zhang, Yuqing, Zheng, Qi, Shang, Xiaoling, Liu, Ni, Ma, Xinchun, Wei, Chenxi, Chen, Hang, Mu, Xin, Wang, Xiuwen, Liu, Yanguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681151/ https://www.ncbi.nlm.nih.gov/pubmed/36426352 http://dx.doi.org/10.3389/fimmu.2022.1030969 |
Ejemplares similares
-
ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022) -
Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
por: Xia, Handai, et al.
Publicado: (2022) -
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
por: Shang, Xiaoling, et al.
Publicado: (2023) -
CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022) -
Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xia, Handai, et al.
Publicado: (2023)